The common sense model applied to hepatitis C: a qualitative analysis of the impact of disease comparison and witnessed death on hepatitis C illness perception by unknown
Safo et al. Harm Reduction Journal  (2015) 12:20 
DOI 10.1186/s12954-015-0054-1RESEARCH Open AccessThe common sense model applied to
hepatitis C: a qualitative analysis of the impact
of disease comparison and witnessed death on
hepatitis C illness perception
Stella A. Safo1*, Abigail Batchelder1,2, Deena Peyser1,3 and Alain H. Litwin1Abstract
Background: Hepatitis C virus (HCV) accounts for 15,000 deaths in the United States yearly because people living
with HCV are not identified in time to seek treatment, are ineligible for or refuse treatment, or face structural
impediments to obtaining treatment such as lack of access to health care or lack of insurance. People who inject
drugs (PWID) comprise a large proportion—estimates of up to 60–70 %—of current and new HCV infected
individuals and face many barriers to completing HCV treatment.
Methods: We conducted 30 qualitative semi-structured interviews of current and former PWID seeking HCV
treatment at an opioid-agonist treatment facility in New York City. We used thematic analysis, informed by
grounded theory, to examine perceptions of HCV and decisions to initiate HCV treatment. We analyzed the themes
that emerged via the common sense model (CSM) of illness perception theoretical framework.
Results: Using thematic analyses, two major themes emerged related to engagement in HCV treatment. First,
participants independently compared HCV to HIV, and in so doing, emphasized the potential fatality of HCV and
the need for treatment. Second, participants described witnessing others suffer or die from untreated HCV and
expressed how these recollections impacted their desire to undergo treatment themselves. Together, these themes
contributed to the way participants perceived HCV and informed their decisions to initiate treatment. Both themes
reflect the CSM’s “self-regulation” process, which posits that understanding the causes and consequences of an
illness impacts one’s ability to seek treatment to overcome this illness state.
Conclusions: This paper offers insight into how clinicians can better understand and utilize HCV illness perceptions
to evaluate willingness to engage in HCV treatment among PWID considering antiviral treatment modalities.
Keywords: Hepatitis C (HCV), HIV/AIDS, Illness perception, Treatment barriers, People who inject drugs (PWID),
Substance useBackground
The burden of disease from hepatitis C virus (HCV) in the
United States remains high, with estimates of approxi-
mately three million infected people and peak rates pre-
dicted for the 2020s–2030s [1]. The development of novel
HCV direct acting antivirals (DAAs)—which improve the
tolerability and convenience of HCV treatment [2, 3]—is* Correspondence: ssafo@montefiore.org
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creativecommons.org/publicdomain/zero/1.0/changing the HCV treatment landscape [4]. Individuals
who could not tolerate HCV treatment in the past are
successfully undergoing treatment with new DAAs to
achieve sustained virologic response (SVR) [3]. How-
ever, among the roughly three million individuals in-
fected with HCV in the US, only 43 % are in medical
care and only 9 % have achieved SVR [5]. In the con-
text of this low treatment uptake, the importance of
addressing barriers to engagement in care among indi-
viduals living with HCV remains a vital public health
effort in HCV control.le distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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60–70 % of new HCV infections in the US [1] and are
particularly vulnerable to HCV infection for various
reasons, including needle sharing and high-risk sexual be-
havior [6–8]. PWID have historically faced structural, sys-
tematic, clinical, and individual-level barriers to engaging in
and completing HCV treatment [9–12], and much research
has investigated factors that impede this group from under-
going HCV treatment [4, 13, 14]. Some inhibiting factors
include social stigmatization, negative encounters with the
medical field, provider reluctance to prescribe HCV-
medications to PWID, lack of availability of effective new
DAAs, and structural barriers such as lack of stable hous-
ing, fear of legal action, and lack of insurance [4, 12–17].
Once PWID living with HCV do engage in care, some may
struggle to complete treatment [14]. Historically, this lack
of treatment initiation was partially due to poor tolerability
of treatment options, consisting primarily of pegylated
interferon alfa-2a and ribavirin, that were lengthy and have
adverse side effects [18, 19]. In countries where DAAs are
available and approved, such as the US [3, 4, 8], their up-
take continues to be affected by PWID’s reluctance to and
difficulty in engaging in HCV care [20–22]. In light of these
challenges, PWID remain an important yet difficult to en-
gage group, whose successful treatment could have a sig-
nificant influence on HCV morbidity and mortality [1, 15].
The extensive body of work on ways in which people
with HCV conceptualize HCV suggests that an individual’s
understanding of his/her illness affects his/her willingness
to get screened for HCV, to consider initiating treatment,
and to continue with treatment once started [4, 20, 23, 24].
Studies using mixed-methods to examine perceptions sur-
rounding HCV treatment uptake in PWID have found that
motivators for seeking treatment include, but are not lim-
ited to, a desire to return to a previously healthy state, ef-
forts to avoid spreading HCV to others, and a desire to
avoid the fear and stigma associated with HCV [4, 12, 13,
17, 24–26]. These studies reinforce that PWID’s illness per-
ceptions of HCV play a role, among many other factors, in
treatment initiation.
The common sense model (CSM)—or illness perception
model—theorizes that individuals create abstract repre-
sentations of their illnesses based on various factors (such
as symptoms or acquired knowledge) to help to explain
their illnesses to themselves and to manage their disease
states [27, 28]. These illness perceptions are based on cog-
nitive and emotional experiences of the threat of the ill-
ness, on experienced symptoms, and on knowledge about
causes and consequences of illness [29]. The process of
“self-regulation” is foundational to the CSM: individuals
engage in a “self-regulation” process that includes prac-
ticing behaviors that will return them to their perceived
normal state of health. According to the CSM, the process
of regaining normal health starts with the belief that oneis afflicted by an illness and that this illness requires some
change in behavior to return to the pre-illness baseline.
Thus, the CSM model posits that an individual’s illness
perception is the primary impetus that drives him or her
to engage in disease modifying behaviors such as en-
gaging in treatment and adhering to medication regi-
mens [30–32]. The CSM has been applied to many
chronic diseases, including diabetes, hypertension, and
asthma [30, 32, 33].
While studies report physical symptoms associated
with HCV [19, 26, 34], the lack of clear and definable
symptom presentation may make HCV difficult for indi-
viduals to recognize [1, 17], which may impact their mo-
tivation to engage in treatment. Therefore, other sources
of information contribute to the way people living with
HCV perceive their illness and feel motivated to seek
out and engage in treatment. Potentially because of the
shared risk factors, several studies have compared HCV to
HIV. Studies using HIV as a benchmark to understand
HCV predominantly find that PWID view HIV as more
deadly than HCV [4, 11, 19, 20, 22–24, 35, 36]. Addition-
ally, potentially as a result of the lack of clear symptom
presentation [17], the impact of witnessing the effect of
HCV in others has been noted as a meaningful experience
among people living with HCV. Witnessing others suffer
from HCV has been shown to both encourage and dis-
courage individuals from seeking treatment [4, 11, 23].
In this study, we sought to elucidate participants’ HCV
illness perceptions among predominantly Hispanic and
African American substance users who had undergone
treatment within an integrated HCV treatment program.
This study builds on existing literature by using qualitative
analysis to evaluate the illness perceptions around HCV
within a longstanding opioid-agonist treatment program
that maintains a nonjudgmental culture and peer involve-
ment in an urban environment. We use exemplary quotes
to highlight the themes of HIV as a benchmark for com-
parison and the impact of witnessing death and suffering
in others as two topics that demonstrate the CSM at work
within illness constructions around HCV.
Methods
Setting
This study is a qualitative sub-study of a randomized
controlled trial (RCT) examining HCV treatment among
people enrolled in an opioid-agonist treatment program
who are current and former injection drug users. The
RCT was conducted between 2008 and 2013 at two pri-
mary addiction care clinics in the Division of Substance
Abuse at Albert Einstein College of Medicine in the
Bronx, New York. It aimed to evaluate the efficacy of
HCV treatment administered as directly observed ther-
apy compared to self-administered therapy. Treatment
was provided as either pegylated interferon alfa-2a and
Safo et al. Harm Reduction Journal  (2015) 12:20 Page 3 of 8ribavirin or as telaprevir in combination with pegylated
interferon alfa-2a and ribavirin. The specifics of the par-
ent RCT trial are described elsewhere [37].
In the qualitative sub-study that provided data for this
paper, providers informed eligible participants about this
study and study staff called individuals who completed
HCV treatment. All individuals reached by phone agreed
to participate, one of whom did not attend two sched-
uled interviews. Study staff did not provide HCV or HIV
education. The full multidisciplinary HCV treatment
team included internal medicine physicians, physician
assistants, nurses, substance abuse counselors, and a
psychiatrist. In addition, HCV support groups and a for-
mal peer educator program were offered at the clinic
sites [38, 39]. Basic education on HCV (transmission,
treatment, etc.) was provided at entrance to the on-site
HCV program, which was remote (>6 months) to the
administration of the semi-structured interview. The
educational curriculum did not formally describe HCV
within the context of HIV.
Participants
We interviewed 30 current or former participants in the
HCV treatment program (Table 1). All participants had
a history of illicit substance use and were seeking drug
treatment at an opioid-agonist program. Active drug use
was not a contraindication to treatment. Approximately
52 % of patients in the program used illicit substances in
the 6 months prior to treatment. All participants were
English speakers and ten were women. Twenty-two partic-
ipants were self-identified as Hispanic, four as African
American, and four as others. All participants were en-
rolled in Medicaid. Seven participants were co-infected
with HIV and HCV. All participants received directly ad-
ministered weekly pegylated interferon injection. Twenty-
two participants were on regimens of pegylated interferon
alfa-2a plus ribavirin only and eight participants also
received telaprevir in combination with pegylated inter-
feron alfa-2a/ribavirin. Twenty participants achieved SVR
and ten did not achieve SVR. Twenty-five participantsTable 1 Demographic characteristics, N = 30
Participants, N (%)
Age (years)a 52 (46–59)
Race
Hispanic 22 (73)
African American 4 (13)
Others 4 (13)
HIV-HCV co-infection 7 (23)
HCV treatmentb 22 (73)
aGiven as median (IQR)
bTreatment administered as pegylated IFN and ribavirin; eight separate
participants received pegylated IFN, telaprevir, and ribavirincompleted HCV treatment, and five discontinued antiviral
treatment early.
Data source and collection
Qualitative interviewer and co-author (AB) conducted
45–90-min-long one-on-one interviews with the partici-
pants at the opioid-agonist clinics. We used a semi-
structured interview guide that explored participants’
perceptions of HCV, experiences initiating and undergo-
ing HCV treatment, HCV medication adherence, and
substance use. The Institutional Review Boards of the
Albert Einstein College of Medicine approved this study.
Analysis
Our thematic analytic approach followed Braun’s six
steps of qualitative analysis and included elements of
grounded theory [40, 41]. Initially, one co-author (AB)
listened to and read all interviews, open coding and not-
ing memos on how themes seemed to relate to one an-
other in the interviews. Open codes, memos, and parts
of transcripts were brought to the full research team
multiple times to discuss concepts and categories as well
as relationships. This process resulted in a working cod-
ing tree that was iteratively refined by obtaining feed-
back on transcripts, codes, concepts, and categories.
This process also resulted in several visual models,
depicting how the codes related to one another in the inter-
views. Subsequently, the transcripts were reviewed by two
co-authors (AB and DP), which resulted in refinement of
the coding tree and theoretical conceptualization. All dis-
crepancies were brought to the full research team, and the
tree was iteratively refined resulting in the final coding
structure. Each transcript was then double coded using the
final coding structure by at least two co-authors (AB, DP,
or SS) blind to each other’s codes. Final coding discrepan-
cies were discussed by co-authors until a decision was
reached. We coded all interviews using NVIVO Version 10.
The themes described in this paper emerged as key fac-
tors relating to participants’ HCV illness perceptions and
reasons for initiating and engaging in HCV treatment. Of
note, while numerous topics emerged throughout the
aforementioned process, we focus on two themes in this
paper that were described as meaningfully associated with
engagement in HCV care: comparison of HIV to HCV
and the impact of witnessing the effect of HCV in others.
These themes were consistent with the CSM of illness
perception; therefore, the results are presented within that
existing theoretical framework.
Results
Through our analyses, two components emerged as pri-
mary factors contributing to participants’ conceptualization
of HCV and seemed related to engagement in HCV treat-
ment. First, all participants spontaneously compared HCV
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ter understand HCV infection. Subthemes for HIV as a
benchmark were HCV as being worse than, the same, or
better than HIV. Second, participants explored how the ex-
perience of witnessing untreated HCV in others affected
their conceptions of HCV illness. Subthemes of witnessing
HCV-related suffering were the impact of witnessing in
loved-ones and in acquaintances and the impact of witnes-
sing in encouraging engagement in treatment.
Component I: HIV as a benchmark for understanding HCV
Many participants described conceptualizing HCV in com-
parison to HIV. They described being unfamiliar with
HCV while being knowledgeable about HIV. Some partici-
pants conceptualized HCV as being less severe than HIV,
some noted HCV to be similar to HIV in severity, and a
few considered HCV to be more severe than HIV. Regard-
less of perceived severity, participants compared HCV to
HIV to better understand the former and, in so doing, de-
pict the application of the CSM.
HCV as less severe than HIV
Those participants who considered HIV to be more severe
than HCV emphasized the fatality and incurability of HIV.
One participant succinctly stated, “HIV is like a death sen-
tence”. Another participant emphasized the fatality of HIV
but instead focused on the lack of curability:
“HIV doesn’t have a treatment—you’re not going to
get well. [Doctors] can tame it. They can treat it, but
you’re not going to get rid of it.”
Another participant noted HCV was “not as serious as
HIV,” but that it is “somewhat” serious “because it’s some-
thing that is quiet in your system.” In contrast to HIV’s
perceived permanence, some participants emphasized the
curability of HCV as a comparison to the incurability of
HIV. For example, this participant explained:
“…If I was told that I had Hep C [HCV], I would say
to myself, at least I don’t have HIV. I’ve seen [that
HCV] wasn’t a real threatening disease. I seen it like a
few pills or whatever and everything is okay.”
HCV as same as HIV
In contrast to the perception of HIV as more severe than
HCV, some participants viewed HCV and HIV as being
equally deadly, particularly if left untreated. For example,
after describing how AIDS reminded him of HCV, this
participant explained:
“They’re [HIV and HCV] all bad, and, I think Hep C
should be looked at just like if you had AIDS…It
could do damage to you, it could kill you.”Another individual noted the similarity in HIV and
HCV but focused instead on the fatality of HCV over
time:
“I view Hep C like HIV, because after the long run,
[HCV] is fatal…you could die off of this. I don’t see it
like a broken arm or a cut in your finger or
something.”
Finally, one participant noted that the similarity of
HIV to HCV is only in the context of individuals not
undergoing HCV treatment, which he explains as “not
taking it seriously:”
“They’re [HIV and HCV] the same. If not dealt with
properly they can both lead to the same place. They
both have to be taken seriously. [HCV] has to be
taken seriously and not judged by how much pain I
have.”
HCV as more severe than HIV
A few individuals viewed HCV as worse than HIV. For
these people, the higher mortality rates of HCV made a
lasting impression on them. For example, when asked to
elaborate on his initial response in which he stated that
HCV is worse than HIV, this participant explained:
“I think [HCV] is worse [than HIV] because there’s
more people infected [with HCV] than people with
HIV. Four times as many. There’s only a million
people infected with HIV, but there’s four million
infected with Hep C. And they do call [HCV] the
silent killer.”
Participants also described the fast-acting nature of
HCV. One participant spoke of knowing an individual
who was co-infected with HIV and HCV; while this
loved-one had untreated HIV for years, once he was di-
agnosed with liver failure caused by HCV, he died very
quickly.
Another participant expounded on the fatality of HCV
infection, especially in the context of high-risk behaviors:
“I think [HCV’s] even worse than HIV now … It’s
killing more people than HIV and quicker, especially if
you drink. And a lot of people do drink and they’re still
drugging so it’s going to kill them faster because they’ve
been using and they’re still in the streets. They got HIV.
But they haven’t died of the HIV… they die of [HCV].”
Component 2: witnessing HCV-related suffering and
death in others
In addition to using HIV as a construct to form HCV ill-
ness perception, the experiences of HCV-infected family
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perceptions. Participants spoke of the impact of illness
in kin, of the impact of illness in acquaintances, and of
the lasting impact of these recollections on their willing-
ness to engage in HCV treatment.
Impact of illness in kin
Descriptions of the impact of HCV in family members
were often very detailed and made a lasting impact on par-
ticipants. One participant recalled witnessing his brother
die of HCV-related liver disease. The following account
describes the participant’s highly detailed memory:
“My brother died of Hep C and then his wife died of
Hep C… that’s a very ugly death—the color, the way
they swell. They lose their leg movements completely,
some arm movements. My brother was never
crippled, but he was in a wheelchair. He couldn’t
walk, he couldn’t even wipe his own butt. It got real
bad…I couldn’t hold a conversation with him because
he’s being fed by tubes, a machine is breathing for
him and he’s swelling up. He always weighed like 160
lbs, he’s solid, the Marine type. [Once he became ill]
he swelled up like three times his size and then he got
black, he had the jaundice thing. I just couldn’t bear
to see him so I told the doctors to pull the plug, just
let him die. It was a hard decision…”
Years later, this participant is able to recall particular
details of his brother’s hospitalization and death,
recounting his brother’s ill appearance and the medical
equipment used near the time of his death. His brother
died an “ugly death,” a description that other partici-
pants echoed with similarly illustrative examples of see-
ing death and suffering in loved-ones.
Some participants did not know at the time that their
loved-ones were dying of liver disease and realized the
true cause of death only after contracting HCV them-
selves. For example, this participant described his child-
hood memory of a sick parent:
“[My mother] had cirrhosis of the liver… she was very
small, and her stomach was so big, and we said to the
[neighborhood] kids she was having a baby. And one
day, one kid said, you said [that she was pregnant] last
year, and the year before that. …I didn’t connect that
with [HCV]. But, as I started going to the groups, and
I started taking notes, and learned that my liver could
get to where she was at the last stop.”
This example exemplifies participants’ vivid recollections
of witnessing loved-ones struggle with HCV, recollections
that haunted this participant years later. Furthermore, this
participant’s verbalization of how he feared he could diejust as his mother died was echoed by other individuals in
our study about their loved-ones.
Impact of illness in acquaintances
In addition to family members, some participants were
moved by the experience of seeing non-family members
suffer from HCV. For example, this participant’s ex-
ample of witnessing HCV-related death is stated in more
general terms, with a reference to “people” rather than
to someone close to him:
“You know, I seen people that died with Hep C and
it’s not pretty. It’s a situation that you suffer after a
while—it starts eating you up—your cells and
everything…” [Italics mine].
Though the individual did not specify who the “people”
were, his statement indicated that the destructive physical
outcomes of HCV left a lasting impression on him. Simi-
larly, another participant referred to a number of un-
named acquaintances living with HCV:
“I feel like [HCV’s] a thing that really kills you. I see a
lot of people die of it now. Now I open my eyes to it
and say ‘wait a minute.’ Thank God I [started
treatment] now, before it got worse since I see so
many people dying of it” [Italics mine].
These accounts suggest that regardless of the degree
of familial or social closeness, witnessing suffering im-
pacts individuals’ perception of HCV.
Impact of witnessing on treatment uptake
Participants described the lasting impact of witnessing
HCV-related deaths. Some participants explicitly stated
how the proximity to HCV’s fatal outcomes encouraged
treatment initiation. For example, one participant related
the effect that his aunt’s experience with HCV had on
his decision to begin treatment:
“I really thought about it because when [my doctor]
told me about all the side effects I was like, ‘I don’t
want to feel like that.’And then again, I thought about
my [deceased] aunt and I said, ‘if I can’t make it
through the whole six months, at least I’ll try.’ That’s
what kept me going, thinking about getting rid of that
thing. Because, [HCV] could kill you.”
Similar to this participant whose aunt’s death inspired
him to overcome his fears of treatment, other partici-
pants emphasized how remembering loved-ones living
with HCV encouraged them to continue treatment des-
pite adverse medication side effects. As this participant
explained:
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this regardless of how I feel about the injections or
the medication or whatever. It’s something that I have
to do because…I knew several individuals that did
have Hep C and they’re no longer with us. They have
died from it. And I don’t want to die.”
Discussion
This study showed that among PWID enrolled in a com-
prehensive multidisciplinary HCV treatment program
within an addiction care center, participants’ HCV illness
perceptions were substantially influenced by compari-
sons to HIV and by witnessing others’ suffer from HCV.
Among this population of ethnic minority PWID, these
components guided participants’ understanding of their
illness states and contributed to the initiation of and per-
severance through HCV treatment. Both thematic find-
ings in our study support the theoretical framework laid
out by the CSM. The CSM posits that “self-regula-
tion”—the process of returning to a previously health
state—is informed by one’s understanding of the causes
and consequences of illness. This understanding encour-
ages individuals to take the steps necessary to return to
a healthy state [28, 31]. In our study, we found that par-
ticipants used perceptions of HIV and witnessing suffer-
ing in others to better to understand the causes and
consequences of HCV infection. Our participants sug-
gest that illness perception may have led to engaging in
healthy behaviors such as treatment uptake. With wit-
nessing, we have clear examples of individuals explicitly
stating how seeing others suffer or die from HCV moti-
vated them to engage in treatment, an example of the
CSM’s focus on consequences at work. Likewise, in
keeping with the CSM’s focus on the need to understand
the cause of the disease, we found that our participants
spoke of HCV within the context of HIV to better
understand HCV severity. With both themes, we see how
the application of the CSM to HCV illness perceptions
broadens participants’ understanding of HCV illness and
facilitates engagement in treatment. This real-world appli-
cation of the CSM suggests that future qualitative studies
of illness perceptions in PWID could be better understood
using this framework.
Furthermore, our study found diverse perceptions of se-
verity of HCV as compared to HIV. Previous studies noted
that PWID with HCV often evoked HIV as a disease for
comparison [19, 20, 23, 24, 35]. However, in these studies,
HIV is described as worse than HCV or as something one
should avoid at all costs. For example, Davis et al. found
that PWID often practiced “safe” drug use behavior out of
a fear of contracting HIV rather than HCV [23]. Likewise,
other qualitative analyses highlighted that among PWID,
HIV was seen as more severe than HCV [20, 24, 35]. The
tendency to view HIV as more severe than HCV may havebeen partially due to greater familiarity with HIV as it has
been a disease in the public consciousness since the early
1980s (compared to HCV’s relatively recent emergence)
and because of the similar risk factors between HCV and
HIV (i.e., both are viral infections transmitted by sharing
injection needles or from unsafe sex). Conversely, the
current tendency to view HCV as severe as or as more se-
vere than HIV may reflect the timing of our study relative
to previous studies because since 2007, HCV has led to
higher mortality than HIV in the United States [42]. Con-
trary to previous literature, our study reveals a more as-
sorted view of HCV where HCV is seen as the same,
better, or worse than HIV. While this comparison to HIV
is made in varying degrees of severity, participants’ ten-
dency to continue to use HIV as a benchmark to under-
stand HCV has clinical implications. Since studies have
found that participants’ knowledge of HCV may often be
misinformed [20, 24, 26], using HIV as a reference point
could offer clinicians one mechanism to address and
counter the incorrect beliefs PWID with HCV may hold
about HCV.
Consistent with previous published literature, we found
that the process of witnessing suffering and death in
others with HCV often greatly influenced participants’ ill-
ness perception by contributing to their understanding of
the consequences of their own infected state [4, 19]. Many
of our participants felt motivated to engage in treatment
after hearing about or witnessing the demise of individuals
who failed to seek treatment. Once initiated, some partici-
pants’ recollections of loved-ones’ health struggles helped
them to continue and complete treatment despite con-
cerns of experiencing adverse medication side effects. Pre-
vious studies have found that witnessing has a dual
impact. Some studies have shown that witnessing HCV-
infected loved-ones undergo such procedures as liver bi-
opsies deterred individuals from wanting to engage in
HCV care [11, 17, 19]. In contrast, others such as Subl-
ette’s study of PWID infected with HCV in West Sydney
found that participants cited loved-ones who had been
screened or treated for HCV as their reasons for engaging
in medical care [4, 22]. Consistent with these latter stud-
ies, participants in our study were more likely to be posi-
tively influenced by the experience of others to engage in
treatment, a finding made unique by our predominantly
minority population receiving care at an opioid-agonist
treatment program. Moreover, we found that not only
loved-ones such as kin or close friends influenced partici-
pants’ views of HCV, but also acquaintances and general
“people,” suggesting that the sphere of influence of witnes-
sing extends beyond one’s immediate circle.
This study has several limitations. Because a number
of individuals were co-infected with HIV, the use of HIV
as a construct for comparison may have been higher
than in another group with less co-infection. We note,
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even in those who were not co-infected. This finding is
consistent with a recent study by Chen et al. on percep-
tions of HCV among HIV mono- and co-infected indi-
viduals, which found that both groups shared similar
knowledge and attitudes towards HCV [43]. Another
limitation is that our study was based on an urban sam-
ple of individuals enrolled in an opioid-agonist treatment
program. It is unclear if similar views would be conveyed
in areas differing from this setting (e.g., non opioid-
agonist, non-urban). Finally, our study interviewed people
who had already completed HCV treatment, which could
have impacted how much participants focused on cer-
tain topics such as medication side effects or import-
ance of cure.
The results of this study have several clinical implica-
tions. By understanding the role illness perceptions may
play as a driver of treatment uptake, HCV providers may
choose to spend some time exploring disease representa-
tions in this group both before and during HCV treat-
ment. Because most people living with HCV likely have
clear illness perceptions of HIV, providers can explore
how conceptualizations of HIV compare and contrast
with individuals’ HCV illness perception. From this
starting point, providers may reinforce accurate illness
perceptions and correct inaccurate ones. Providers can
also explore whether patients have witnessed the death
of anyone with HCV and can evaluate how this experi-
ence shaped his/her illness perception. Providers may
then use direct discussion, support groups, or peer edu-
cators to help modify illness perceptions based on wit-
nessed death or suffering. Specifically, we note that
while clinical providers such as medical doctors or nurse
practitioners are often at the forefront of delivering
HCV treatment, we believe that counseling around en-
gaging in HCV treatment can be done via peer-led sup-
port groups, peers, and hepatitis educators as well.
Conclusions
Our study demonstrates that PWID with HCV formed nu-
merous views of HCV illness that were consistent with the
common sense model. Specifically, participants’ HCV
illness perceptions were founded on using HIV as a
benchmark to understand HCV and on the impact of wit-
nessing HCV-related suffering in others. These illness per-
ceptions are important because they may inform how
providers engage PWID in HCV treatment. The emergence
of novel and effective DAAs with short treatment courses
greatly expands the potential to successfully cure individ-
uals with HCV. Within this landscape of improved treat-
ment options, people living with HCV should be urgently
identified and engaged in care. We suggest that a focus on
illness perception may be one tool, among many, in the ar-
senal to successfully engage PWID living with HCV in care.Abbreviations
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